Copyright © 2021. Inderes Oyj. All rights reserved.

Genovis AB

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
13.8.
2021

Redeye returns with a follow-up note to Genovis’ Q2’21 report and continues to have a positive long-term view of the case.

Muut analyysit
12.8.
2021

Redeye regards Genovis’ Q2’21 report as solid and finds it encouraging to see continued high growth in the core Analytics segment.

Muut analyysit
9.6.
2021

In this note, Redeye elaborates on why we see the cross-licensing agreement with GlycoT Therapeutics as strategically interesting.

Muut analyysit
30.4.
2021

Redeye provides a follow-up note to Genovis Q1'21 report, with updated estimates and valuation.

Muut analyysit
29.4.
2021

Redeye’s first impression of Genovis Q1’21 is that it is a pretty solid report in the core business, given that customer activity remains regionally sluggish due to the pandemic.

Genovis AB